# US 9,433,633 B2 · Methods for treating diseases of altered IgE regulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,433,633 B2
- Document ID: US9433633B2
- Status: Granted
- Kind: B2
- Application number: 12/026,172
- Filed: 2008-02-05
- Published: 2008-08-07
- Granted: 2016-09-06
- Earliest claimed: 2007-02-06
- Assignees: Martin Heath Bluth
- Applicants: Martin Heath Bluth
- Inventors: Martin Heath Bluth
- Web page: https://patentgrep.com/patent/US9433633B2

## CPC

- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61P 11/06: Antiasthmatics
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Techniques for treating one or more diseases of altered IgE regulation in a patient are provided. For example, a technique for treating one or more diseases of altered IgE regulation in a patient includes the step of administering a therapeutically effective amount of one or more sophorolipids to the patient in a manner which decreases IgE production in the patient. Further, the technique for treating one or more diseases of altered IgE regulation may include administering a therapeutically effective amount of one or more sophorolipids intravenously, intramuscularly, as an inhalant, subcutaneously, topically and/or systemically.

## Claims

### Claim 1

A method of treating asthma comprising administering one or more sophorolipids to a patient in need thereof in an amount which is effective to decrease IgE production wherein the one or more sophorolipids are administered one or more times daily for a period of one or more days and in an amount in the range of 0.5 milligrams per kilogram of body weight of the patient to 750 milligrams per kilogram of body weight of the patient.

### Claim 2 (depends on 1)

The method of claim 1, wherein the step of administering one or more sophorolipids comprises dissolving the one or more sophorolipids in one or more pharmaceutically acceptable carriers.

### Claim 3 (depends on 2)

The method of claim 2, wherein the one or more carriers comprise at least one of saline, dimethyl sulfoxide (DMSO), sucrose or ethanol.

### Claim 4 (depends on 1)

The method of claim 1, wherein the one or more sophorolipids is administered intravenously.

### Claim 5 (depends on 1)

The method of claim 1, wherein the one or more sophorolipids is administered intramuscularly.

### Claim 6 (depends on 1)

The method of claim 1, wherein the one or more sophorolipids is administered as an inhalant.

### Claim 7 (depends on 6)

The method of claim 6, wherein the inhalant comprises an aerosol.

### Claim 8 (depends on 6)

The method of claim 6, wherein the one or more sophorolipids are in the form of one or more particles, and wherein each particle has a size of about one micron in diameter to about ten microns in diameter.

### Claim 9 (depends on 1)

The method of claim 1, wherein the one or more sophorolipids are administered subcutaneously.

### Claim 10 (depends on 1)

The method of claim 1, wherein the one or more sophorolipids are administered topically.

### Claim 11 (depends on 10)

The method of claim 10, wherein the one or more sophorolipids are topically administered as a cream, salve, transdermal patch or ointment.

### Claim 12 (depends on 1)

The method of claim 1, wherein the one or more sophorolipids are administered systemically.

### Claim 13 (depends on 1)

The method of claim 1, wherein the one or more sophorolipids are administered at a site of inflammation or rejection.